Company: INFY
Filing Date: 2025-07-01
Form Type: 20-F
Source: 0000950170-25-091925
Chunk: 250

Company: Infosys Ltd
Filing Date: 2025-07-01
Form: 20-F
Item: Item 18
Chunk 250
---
Gross carrying value as of April 1, 2022                             274               121                40                    90                   525    
Additions during the period                                            —                 8                 —                     —                     8    
Acquisition through business combination (Refer Note 2.10)            34                 –                                                            41    
Translation differences                                                (   )             (   )            (1    )                –                    (4   )
Gross carrying value as of March 31, 2023                            307               127                42                    94                   570    
Accumulated amortization as of April 1, 2022                        (169   )           (75   )           (19    )              (37    )             (300   )
Amortization expense                                                 (29   )           (10   )            (6    )              (15    )              (60   )
Translation differences                                                2                 —                 1                     —                     3    
Accumulated amortization as of March 31, 2023                       (196   )           (85   )           (24    )              (52    )             (357   )
Carrying value as of March 31, 2023                                  111                42                18                    42                   213    
Carrying value as of April 1, 2022                                   105                46                21                    53                   225    
Estimated Useful Life (in years)                                    1-15              3-10              3-10                   3-7                          
Estimated Remaining Useful Life (in years)                          1-11               1-6               1-7                   1-5                          

* Majorly includes intangibles related to vendor relationships

The amortization expense has been included under depreciation and amortization expense under cost of sales in the consolidated statement of comprehensive income.

Research and development expense recognized in the consolidated statement of comprehensive income, for fiscal 2025, 2024 and 2023 was $153 million, $135 million and $129 million, respectively.

 

2.10 Business combinations

Accounting Policy:

Business combinations have been accounted for using the acquisition method under the provisions of IFRS 3 (Revised), Business Combinations.

The purchase price in an acquisition is measured at the fair value of the assets transferred, equity instruments issued and liabilities incurred or assumed at the date of acquisition, which is the date on which control is